LLYEli Lilly and CompanySigning up patients
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Breast Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 600 (planned)
- Started
- May 13, 2026
- Main results expected
- Jan 2029
- Fully finished
- Dec 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change from Baseline in Antigen Kiel (Ki-67) Expression
Measured over: Baseline, Day 29
Rate of Symptomatic Ovarian Cysts
Measured over: Up to Day 180
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07287098 · record last updated 2026-11-04 · checked 2026-11-09 15:36 UTC